Khitam Muhsen1, Nimrod Maimon2,3,4, Ami Mizrahi2, Omri Bodenheimer2, Dani Cohen1, Michal Maimon3,4, Itamar Grotto3,5, Ron Dagan3. 1. Department of Epidemiology and Preventive Medicine, School of Public Health, The Sackler Faculty, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel. 2. Israel Ministry of Health, "Senior Shield" Project, Hevel Modi\'in Regional Council, Airport city, Israel. 3. Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. 4. Soroka University Medical Center, Beer-Sheva, Israel. 5. Ministry of Health, Jerusalem, Israel.
Abstract
BACKGROUND: We assessed vaccine effectiveness (VE) of BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) acquisition among healthcare workers (HCWs) of long-term care facilities (LTCFs). METHODS: This prospective study, in the framework of the "Senior Shield" program in Israel, included routine weekly nasopharyngeal SARS-CoV-2 RT-PCR testing from all LTCF HCWs since July 2020. All residents and 75% of HCWs were immunized between December 2020 and January 2021. The analysis was limited to HCWs adhering to routine testing. Fully vaccinated (14+ days after second dose; n = 6960) and unvaccinated (n = 2202) HCWs were simultaneously followed until SARS-CoV-2 acquisition or end of follow-up, 11 April 2021. Hazard ratios (HRs) for vaccination versus no vaccination were calculated (Cox proportional hazards regression models, adjusting for sociodemographics and residential-area COVID-19 incidence). VE was calculated as (1- HR) × 100. RT-PCR cycle threshold (Ct) values were compared between vaccinated and unvaccinated HCWs. RESULTS: At >14 days post-second dose, 40 vaccinated HCWs acquired SARS-CoV-2 (median follow-up, 66 days; cumulative incidence, 0.6%) versus 84 unvaccinated HCWs (median follow-up, 43 days; cumulative incidence, 5.1%) (HR, .11; 95% CI, .07-.17; unadjusted VE, 89%; 95% CI, 83-93%). Adjusted VE >7 and >14 days post-second dose were similar. The median PCR Ct targeting the ORF1ab gene among 20 vaccinated and 40 unvaccinated HCWs was 32.0 versus 26.7, respectively (P value = .008). CONCLUSIONS: VE following 2 doses of BNT162b2 against SARS-CoV-2 acquisition in LTCF HCWs was high. The lower viral loads among SARS-CoV-2-positive HCWs suggest further reduction in transmission.
BACKGROUND: We assessed vaccine effectiveness (VE) of BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) acquisition among healthcare workers (HCWs) of long-term care facilities (LTCFs). METHODS: This prospective study, in the framework of the "Senior Shield" program in Israel, included routine weekly nasopharyngeal SARS-CoV-2 RT-PCR testing from all LTCF HCWs since July 2020. All residents and 75% of HCWs were immunized between December 2020 and January 2021. The analysis was limited to HCWs adhering to routine testing. Fully vaccinated (14+ days after second dose; n = 6960) and unvaccinated (n = 2202) HCWs were simultaneously followed until SARS-CoV-2 acquisition or end of follow-up, 11 April 2021. Hazard ratios (HRs) for vaccination versus no vaccination were calculated (Cox proportional hazards regression models, adjusting for sociodemographics and residential-area COVID-19 incidence). VE was calculated as (1- HR) × 100. RT-PCR cycle threshold (Ct) values were compared between vaccinated and unvaccinated HCWs. RESULTS: At >14 days post-second dose, 40 vaccinated HCWs acquired SARS-CoV-2 (median follow-up, 66 days; cumulative incidence, 0.6%) versus 84 unvaccinated HCWs (median follow-up, 43 days; cumulative incidence, 5.1%) (HR, .11; 95% CI, .07-.17; unadjusted VE, 89%; 95% CI, 83-93%). Adjusted VE >7 and >14 days post-second dose were similar. The median PCR Ct targeting the ORF1ab gene among 20 vaccinated and 40 unvaccinated HCWs was 32.0 versus 26.7, respectively (P value = .008). CONCLUSIONS: VE following 2 doses of BNT162b2 against SARS-CoV-2 acquisition in LTCF HCWs was high. The lower viral loads among SARS-CoV-2-positive HCWs suggest further reduction in transmission.
Authors: Melissa M Higdon; Brian Wahl; Carli B Jones; Joseph G Rosen; Shaun A Truelove; Anurima Baidya; Anjalika A Nande; Parisa A ShamaeiZadeh; Karoline K Walter; Daniel R Feikin; Minal K Patel; Maria Deloria Knoll; Alison L Hill Journal: Open Forum Infect Dis Date: 2022-04-18 Impact factor: 4.423
Authors: Yun Shan Goh; Angeline Rouers; Nina Le Bert; Wan Ni Chia; Jean-Marc Chavatte; Zi Wei Chang; Nicole Ziyi Zhuo; Matthew Zirui Tay; Laurent Renia; Siew-Wai Fong; Yi-Hao Chan; Chee Wah Tan; Nicholas Kim-Wah Yeo; Siti Naqiah Amrun; Yuling Huang; Joel Xu En Wong; Pei Xiang Hor; Chiew Yee Loh; Bei Wang; Eve Zi Xian Ngoh; Siti Nazihah Mohd Salleh; Guillaume Carissimo; Samanzer Dowla; Alicia Jieling Lim; Jinyan Zhang; Joey Ming Er Lim; Cheng-I Wang; Ying Ding; Surinder Pada; Louisa Jin Sun; Jyoti Somani; Eng Sing Lee; Desmond Luan Seng Ong; Yee-Sin Leo; Paul A MacAry; Raymond Tzer Pin Lin; Lin-Fa Wang; Ee Chee Ren; David C Lye; Antonio Bertoletti; Barnaby Edward Young; Lisa F P Ng Journal: Nat Commun Date: 2022-08-08 Impact factor: 17.694
Authors: Pablo Chico-Sánchez; Paula Gras-Valentí; Natividad Algado-Sellés; Natali Jiménez-Sepúlveda; Hermelinda Vanaclocha; Salvador Peiró; Javier S Burgos; Ana Berenguer; David Navarro; José Sánchez-Payá Journal: Prev Med Date: 2022-08-31 Impact factor: 4.637